BioOra is a brand dedicated to supporting patients battling advanced cancer. They understand the importance of time when it comes to cancer treatment, which is why they have optimized every step of the process to manufacture cGMP CAR T-cells as quickly as possible. Their commitment to stringent controls and utmost diligence ensures that every patient receives their clinical-grade cells promptly.

As CAR T-cell therapy transforms the clinical management of oncologic patients, BioOra is at the forefront of this innovative journey. They are proudly supported by Bridgewest Ventures, a company with a strong track record in incubating and launching global innovation-led companies. Bridgewest Ventures leverages its deep technology experience and extensive connections to transform innovative opportunities into world-class companies.

BioOra also collaborates with the Malaghan Institute of Medical Research, New Zealand's world-leading independent biomedical research institute. Together, they are automating the production of CAR T-cells to support clinical trials, specifically for patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Furthermore, BioOra is part of Callaghan Innovation's Technology Incubator Programme, aligning with their mission to foster innovation in New Zealand.

Callaghan Innovation, New Zealand's innovation agency, provides tailored technical solutions and grants co-funding to empower innovators. BioOra, derived from the Greek words 'bios' meaning life and 'ora' meaning time, represents the gift that CAR T-cell therapy can offer. With locations in Wellington, New Zealand, and San Diego, California, BioOra is committed to making a difference in cancer treatment